ATE447709T1 - Verfahren zum bereitstellen von natürlichen arzneimittel mit hohen therapeutischen indizes - Google Patents

Verfahren zum bereitstellen von natürlichen arzneimittel mit hohen therapeutischen indizes

Info

Publication number
ATE447709T1
ATE447709T1 AT03785733T AT03785733T ATE447709T1 AT E447709 T1 ATE447709 T1 AT E447709T1 AT 03785733 T AT03785733 T AT 03785733T AT 03785733 T AT03785733 T AT 03785733T AT E447709 T1 ATE447709 T1 AT E447709T1
Authority
AT
Austria
Prior art keywords
medicinal products
high therapeutic
therapeutic indices
natural medicinal
providing natural
Prior art date
Application number
AT03785733T
Other languages
English (en)
Inventor
Jean-Louis Escary
Original Assignee
Genodyssee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genodyssee filed Critical Genodyssee
Application granted granted Critical
Publication of ATE447709T1 publication Critical patent/ATE447709T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT03785733T 2002-11-07 2003-11-06 Verfahren zum bereitstellen von natürlichen arzneimittel mit hohen therapeutischen indizes ATE447709T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02292787A EP1418428A1 (de) 2002-11-07 2002-11-07 Verfahren zur Bereitstellung von natürlichen therapeutischen Agenzien mit hohem therapeutischen Index
US10/315,493 US20040009161A1 (en) 2002-07-11 2002-12-10 Method for providing natural therapeutic agents with high therapeutic index
PCT/EP2003/013695 WO2004042394A2 (en) 2002-11-07 2003-11-06 Method for providing natural therapeutic agents with high therapeutic index

Publications (1)

Publication Number Publication Date
ATE447709T1 true ATE447709T1 (de) 2009-11-15

Family

ID=30011282

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03785733T ATE447709T1 (de) 2002-11-07 2003-11-06 Verfahren zum bereitstellen von natürlichen arzneimittel mit hohen therapeutischen indizes

Country Status (7)

Country Link
US (2) US20040009161A1 (de)
EP (2) EP1418428A1 (de)
AT (1) ATE447709T1 (de)
AU (1) AU2003294782A1 (de)
CA (2) CA2413981A1 (de)
DE (1) DE60329932D1 (de)
WO (1) WO2004042394A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
US20070227907A1 (en) * 2006-04-04 2007-10-04 Rajiv Shah Methods and materials for controlling the electrochemistry of analyte sensors
US9492111B2 (en) * 2002-04-22 2016-11-15 Medtronic Minimed, Inc. Methods and materials for stabilizing analyte sensors
US7813780B2 (en) 2005-12-13 2010-10-12 Medtronic Minimed, Inc. Biosensors and methods for making and using them
US9237865B2 (en) * 2002-10-18 2016-01-19 Medtronic Minimed, Inc. Analyte sensors and methods for making and using them
US20050272989A1 (en) * 2004-06-04 2005-12-08 Medtronic Minimed, Inc. Analyte sensors and methods for making and using them
JP4960702B2 (ja) 2003-09-18 2012-06-27 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 高性能エネルギー蓄積装置
AR064292A1 (es) 2006-12-12 2009-03-25 Commw Scient Ind Res Org Dispositivo mejorado para almacenamiento de energia
AR067238A1 (es) 2007-03-20 2009-10-07 Commw Scient Ind Res Org Dispositivos optimizados para el almacenamiento de energia
CN102484245B (zh) 2009-04-23 2015-11-25 古河电池株式会社 铅蓄电池用负极板的制造方法以及铅蓄电池
EP2471129B1 (de) 2009-08-27 2016-11-16 Commonwealth Scientific and Industrial Research Organisation Stromspeichervorrichtung und elektrode dafür
JP5711483B2 (ja) 2009-08-27 2015-04-30 古河電池株式会社 鉛蓄電池用複合キャパシタ負極板の製造法及び鉛蓄電池
JP5797384B2 (ja) 2009-08-27 2015-10-21 古河電池株式会社 鉛蓄電池用複合キャパシタ負極板及び鉛蓄電池
US8660628B2 (en) * 2009-12-21 2014-02-25 Medtronic Minimed, Inc. Analyte sensors comprising blended membrane compositions and methods for making and using them
JP2012133959A (ja) 2010-12-21 2012-07-12 Furukawa Battery Co Ltd:The 鉛蓄電池用複合キャパシタ負極板及び鉛蓄電池
US9626432B2 (en) * 2013-09-09 2017-04-18 International Business Machines Corporation Defect record classification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795976A (en) * 1995-08-08 1998-08-18 The Board Of Trustees Of The Leland Stanford Junior University Detection of nucleic acid heteroduplex molecules by denaturing high-performance liquid chromatography and methods for comparative sequencing
US6020165A (en) * 1998-11-10 2000-02-01 Incyte Pharmaceuticals, Inc. Cytikine signal regulators
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823764B1 (fr) * 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17

Also Published As

Publication number Publication date
US20040009161A1 (en) 2004-01-15
EP1561105B1 (de) 2009-11-04
WO2004042394A2 (en) 2004-05-21
CA2504980A1 (en) 2004-05-21
EP1418428A1 (de) 2004-05-12
US20060094641A1 (en) 2006-05-04
AU2003294782A1 (en) 2004-06-07
CA2413981A1 (en) 2004-05-07
AU2003294782A8 (en) 2004-06-07
EP1561105A2 (de) 2005-08-10
DE60329932D1 (de) 2009-12-17
WO2004042394A3 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
ATE447709T1 (de) Verfahren zum bereitstellen von natürlichen arzneimittel mit hohen therapeutischen indizes
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
ATE330606T1 (de) Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden
CY1107961T1 (el) Υλικα οφθαλμικων και ωτορινολαρυγγολογικων συσκευων
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
NO20061239L (no) Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
DE60134962D1 (de) Anti-ccr4 antikörper und fragmente davon
ATE307593T1 (de) Mit einem tensid co-mikronisiertes progestin, pharmazeutische zusammensetzung dieses enthaltend,verfahren zu deren herstellung sowie verwendung
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
ATA182898A (de) Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
FR2659084B1 (fr) Composition de caoutchouc, notamment pour chapes de pneus et semelles de chaussures.
DE60336068D1 (de) Antikörper gerichtet gegen oxidierten Apolipoprotein B
ATE459703T1 (de) Neuer brevibacillus choshinensis sowie verfahren zur herstellung von protein unter verwendung der mikrobe als wirt
DE60225579D1 (de) Photochrome härtbare zusammensetzung mit hohen brechungindex und verfahren zu seiner herstellung
DE68904475T2 (de) Gewisse paf-antagonist/antihistamin-mischungen und verfahren.
DE50207732D1 (de) Kernhydrierte blockcopolymere mit assymetrischem aufbau
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
DE50302673D1 (de) Substituierte thiophene, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
WO2003104481A3 (en) PROCESSES
ATE473001T1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
DE60319681D1 (de) Zytokapazität-verfahren
ATE433326T1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
AU2003230830A8 (en) Treatment of type 1 diabetes before and after expression of predisposition markers
EP1229423A3 (de) Verfahren zur Bereitstellung eines geräteindividuellen Gerätecodes für ein elektronisches Gerät

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties